BiotechTube

Avacincaptad pegol (ACP)

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy, Macular Degeneration

Trial Timeline

Jan 22, 2025 → Jan 31, 2030

NCT ID
NCT06779773

About Avacincaptad pegol (ACP)

Avacincaptad pegol (ACP) is a pre-clinical stage product being developed by Astellas Pharma for Geographic Atrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06779773. Target conditions include Geographic Atrophy, Macular Degeneration.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT06779773Pre-clinicalRecruiting

Competing Products

20 competing products in Geographic Atrophy

See all competitors
ProductCompanyStageHype Score
avacincaptad pegolAstellas PharmaPhase 3
77
Avacincaptad PegolAstellas PharmaPhase 2/3
65
avacincaptad pegolAstellas PharmaApproved
85
Avacincaptad Pegol + ShamAstellas PharmaPhase 3
77
ABBV-6628 + SYFOVREAbbViePhase 1/2
41
FWY003 + PlaceboNovartisPhase 2
52
CLG561 + LFG316 + Sham injectionNovartisPhase 2
52
LFG316 + Sham + LFG316 Lower doseNovartisPhase 2
52
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
RO7669330 + Syfovre™ + Izervay™RochePhase 1
33
RO7303359RochePhase 1
33
SAR446597 + Sham ComparatorSanofiPhase 1/2
40
PozelimabRegeneron PharmaceuticalsPhase 1
32
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)Ionis PharmaceuticalsPhase 2
49
Tinlarebant + PlaceboBelite BioPhase 3
74
PegcetacoplanApellis PharmaceuticalsPre-clinical
18
APL-2 + APL-2Apellis PharmaceuticalsPhase 3
72
APL-2, PegcetacoplanApellis PharmaceuticalsPhase 3
72

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85